Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Fryzek

Internal Medicine Council Bluffs, IA Medical Doctor

NPI 1417020595 CMS profile 290865

201 Ridge St, Suite 202, Council Bluffs, IA 51503

Open in the dashboard

General payments

$28,200

1,106 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Fryzek of Council Bluffs, IA is reported in the CMS Open Payments database as having received $28,200 across 1,106 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,455 140
2024 General $2,914 140
2023 General $3,894 156
2022 General $4,227 149
2021 General $4,594 180
2020 General $3,901 159
2019 General $5,216 182

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Fryzek
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Matthew Fryzek were reported at $3,455. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Matthew Fryzek Internal Medicine median Middle half National median
2019 $5,216 $159 $48–$570 $163
2020 $3,901 $119 $33–$402 $114
2021 $4,594 $135 $37–$521 $132
2022 $4,227 $141 $42–$496 $149
2023 $3,894 $149 $45–$519 $160
2024 $2,914 $154 $47–$537 $164
2025 $3,455 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $3,129 75 payments
  2. Novo Nordisk Inc $2,039 99 payments
  3. Amgen Inc. $1,789 96 payments
  4. Pfizer Inc. $1,435 74 payments
  5. Gilead Sciences, Inc. $1,404 41 payments
  6. AbbVie, Inc. $1,365 56 payments
  7. Janssen Pharmaceuticals, Inc $1,245 53 payments
  8. GlaxoSmithKline, LLC. $1,231 58 payments
  9. E.R. Squibb & Sons, L.L.C. $1,209 39 payments
  10. Lilly USA, LLC $1,144 73 payments
  11. Other $12,211 442 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $27,956 1,097 payments
  2. Education $244 9 payments
Products named General payments · program years 2019–2025
  1. RYBELSUS $1,543 72 payments
  2. FARXIGA $1,470 43 payments
  3. Ozempic $1,257 80 payments
  4. XARELTO $1,074 49 payments
  5. Kerendia $1,038 36 payments
  6. ELIQUIS $1,010 41 payments
  7. TRELEGY ELLIPTA $818 48 payments
  8. EVENITY $791 45 payments
  9. UBRELVY $766 24 payments
  10. Repatha $662 40 payments
  11. Other $20,970 931 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 234 drugs

Part D claims

21,332

Median for Internal Medicine: 777

Drug cost

$1,914,587

Median for Internal Medicine: $73,373

Branded share of claims

22.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 308 $247,214
Ozempic Semaglutide Brand 127 $145,873
Farxiga Dapagliflozin Propanediol Brand 158 $136,188
Xarelto Rivaroxaban Brand 161 $124,255
Jardiance Empagliflozin Brand 156 $116,709
Tresiba Flextouch U-200 Insulin Degludec Brand 75 $91,432
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 112 $89,399
Mounjaro Tirzepatide Brand 72 $85,545
Myrbetriq Mirabegron Brand 131 $63,089
Synjardy Xr Empagliflozin/Metformin Hcl Brand 44 $55,336

The 10 drugs with the highest cost, of 234 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$227,445

Of which drugs: $9,645

Medicare patients

499

Average age 76

Services billed

5,380

249 women, 250 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 67%
Diabetes 29%
Chronic kidney disease 28%
Ischemic heart disease 27%
Atrial fibrillation 20%
Cancer 20%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 156 156 $9,114
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 21 21 $460
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 97 $65

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 39 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
$153 — —
ZENPEP
$153 — —
TRELEGY ELLIPTA
$148 112 —
Epclusa
$120 — —
LEQVIO
$119 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 39 with Patron

Records

1,106 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record